Celldex Therapeutics, Inc. Stock Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 2.16B 1.92B 1.78B 1.62B 3.06B 205B 3.11B 21.41B 8.39B 107B 8.11B 7.94B 341B | P/E 2026 * |
-6.56x | P/E 2027 * | -6.45x |
|---|---|---|---|---|---|
| Enterprise Value | 1.5B 1.33B 1.24B 1.12B 2.12B 142B 2.16B 14.85B 5.82B 74.27B 5.63B 5.51B 237B | EV / Sales 2026 * |
811x | EV / Sales 2027 * | 154x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 2.16B | |
| -6.60% | -8.56% | +42.79% | +64.16% | 65B | |
| -4.09% | -0.11% | +2.31% | +54.81% | 51.19B | |
| +0.03% | +5.56% | +10.18% | +41.75% | 51.2B | |
| -1.53% | +2.70% | +29.72% | +34.13% | 43.93B | |
| -1.34% | +4.12% | +16.05% | +112.18% | 41.96B | |
| -5.97% | -6.22% | +258.21% | +421.57% | 38.14B | |
| +6.53% | +8.02% | +15.74% | +53.94% | 33.24B | |
| -0.90% | -10.49% | +31.48% | -1.63% | 25.2B | |
| -2.76% | -9.54% | -16.53% | -9.55% | 22.03B | |
| Average | -0.58% | -1.67% | +43.33% | +85.71% | 41.32B | |
| Weighted average by Cap. | -2.22% | -1.21% | +43.56% | +88.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.85M 1.64M 1.52M 1.39M 2.62M 176M 2.66M 18.32M 7.18M 91.62M 6.94M 6.79M 292M | 9.95M 8.85M 8.2M 7.46M 14.08M 945M 14.31M 98.58M 38.65M 493M 37.36M 36.56M 1.57B |
| Net income | -319M -284M -263M -239M -451M -30.29B -459M -3.16B -1.24B -15.81B -1.2B -1.17B -50.39B | -361M -321M -297M -271M -511M -34.26B -519M -3.57B -1.4B -17.88B -1.35B -1.33B -56.99B |
| Net Debt | -662M -589M -546M -496M -937M -62.86B -952M -6.56B -2.57B -32.8B -2.49B -2.43B -105B | -633M -563M -522M -475M -896M -60.12B -910M -6.27B -2.46B -31.37B -2.38B -2.33B -100B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
